This report was first published by Endpoints News. To see the original version, click here
The road to Amicus Therapeutics’ $4.8 billion exit to BioMarin last month included a previously undisclosed acquisition offer from another biopharma, quiet dinners between CEOs and a months-long push to settle a legal dispute.
The details are included in a new regulatory document that outlines the deal’s history and the run-up to the eventual $ 14.50-a-share price for the Princeton, NJ-based biotech. Amicus had been considering strategic alternatives since at least 2013, when it engaged Goldman Sachs to look at potential deals, according to the Wednesday night SEC filing.
您已阅读26%（667字），剩余74%（1857字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。